Armata Pharmaceuticals Announces That CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
Armata Pharmaceuticals Announces That CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for LOS ANGELES, Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Dr. Deborah Birx, Chief Executive Officer, will deliver a presentation at 1:15pm ET at the 5th Annual Phage Futures Annual Meeting, which is being held November 19th in Boston, MA.
洛杉矶，2024年11月19日 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (纽交所美国: ARMP) （"Armata"或"公司"），是一家专注于针对抗生素耐药和难治性细菌感染的病原特异性噬菌体治疗的临床阶段生物技术公司，今天宣布首席执行官德博拉·比尔克斯博士将于东部时间下午1:15在第5届噬菌体期货年会上发表演讲，该会议于11月19日在马萨诸塞州波士顿举行。
For more information:
了解更多信息：
About Armata Pharmaceuticals, Inc.
关于Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Armata是一家专注于利用其专有的噬菌体技术开发针对抗生素耐药和难治性细菌感染的病原特异性噬菌体治疗药物的临床阶段生物技术公司。Armata正在开发和推进一系列天然和合成噬菌体候选药物，其中包括绿脓杆菌、金黄色葡萄球菌和其他病原体的临床候选药物。Armata致力于利用从实验室到临床的药物开发专业知识推动噬菌体疗法，包括内部研发噬菌体特异性cGMP制造。
Media Contacts:
媒体联系方式:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234
在Armata：
Pierre Kyme
Armata制药公司
[email protected]
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569
投资者关系:
乔伊斯·阿莱尔
LifeSci Advisors, LLC
[email protected]
212-915-2569
SOURCE Armata Pharmaceuticals, Inc.
来源：Armata Pharmaceuticals，Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新闻在PRNEWSWIRE.COM上特色呈现吗？
